List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
As the lab–data science divide continues, Ian Kerman looks ahead to a future of deeper collaboration – one where shared skills, smarter tools and a shift in mindset could finally break down the barriers. In this second interview, he shares his vision, practical ideas and advice for the next generation…
Researchers at POSTECH have developed a new 3D brain model that closely mimics the structure and function of human brain tissue – marking a major advance in early disease detection.
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
EPFL scientists have engineered virus-inspired DNA aptamers that bind infection targets with record selectivity. This innovation could change how we diagnose and treat infectious diseases.
Nearly a billion people are affected by chronic organ scarring, yet treatments remain limited. Now, Duke-NUS researchers have compiled a scientific ‘handbook’ of immune cell insights that could fast-track breakthroughs in fibrosis therapy.
5 June 2025 | By WuXi Biologics
Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.
Researchers at the University of Illinois have achieved the first successful metabolic labelling of platelets, a key step toward using them in targeted drug delivery. The technique could enable short-lived, precision therapies for cancer, immune conditions, and clotting disorders.
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
Antibody-drug conjugates (ADCs) are transforming cancer therapy by enabling targeted drug delivery with minimised side effects, but their complex structure presents unique challenges in bioanalysis. This article explores cutting-edge strategies for optimising ADC evaluation, from quantifying drug-to-antibody ratios (DAR) to overcoming hurdles like payload interference and stability.
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
4 April 2025 | By Eurofins Discovery
Dr. Francisca Neethling from Eurofins Discovery explores the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
21 March 2025 | By Abzena
Watch our webinar with Abzena’s experts to explore practical solutions for overcoming chemistry, manufacturing and regulatory challenges in antibody-oligonucleotide conjugate (AOC) development, enabling progress for previously untreatable diseases.
